Breaking News Instant updates and real-time market news.

TLRY

Tilray

$22.16

0.57 (2.64%)

16:09
11/04/19
11/04
16:09
11/04/19
16:09

Tilray initiated with a Neutral at Cantor Fitzgerald

Cantor Fitzgerald analyst Pablo Zuanic initiated coverage of Tilray with a Neutral rating and $20 price target.

  • 12

    Nov

  • 12

    Nov

TLRY Tilray
$22.16

0.57 (2.64%)

10/10/19
STFL
10/10/19
NO CHANGE
STFL
Hexo miss further damages cannabis industry credibility, says Stifel
Hexo (HEXO) this morning provided a preliminary update for its fiscal Q4 with revenue coming in below the consensus estimate and well below the "double" offered by management mid-quarter during the Q3 earnings call, Stifel analyst Andrew Carter tells investors in a research note. The preannouncement is "another headline damaging" the cannabis industry's credibility, Carter tells investors in a research note. For companies facing "significant financing risk," the analyst believes a "real segregation of assets will occur." Some companies will face significant dilution due to onerous financing terms while others will simply be unable to access capital, predicts the analyst. Carter thinks the macro environment will continue to be difficult and that the capital positions of Canopy Growth (CGC) and Cronos Group (CRON) are "clear competitive advantages." Those two have the ability to continue executing their business plans while capitalizing on the sector weakness, which "will only intensify from here," says Carter. Other names in the cannabis space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY) and Zynerba (ZYNE). Shares of Hexo are down 24%, or 90c, to $2.78 in early trading.
10/14/19
GHSC
10/14/19
DOWNGRADE
GHSC
Neutral
Canopy, Hexo downgraded to Neutral as Seaport Global cuts cannabis estimates
Seaport Global analyst Brett Hundley lowered his sales and earnings forecasts for the conventional Canadian cannabis companies he covers as part of a broader reset of expectations for the Canadian cannabis space. As part of the broader changes, he downgraded Canopy Growth (CGC) and Hexo Corp. (HEXO), both to Neutral from Buy. Hundley has lowered his FY21 view for Canopy's revenue to $475.5M and his EBITDA forecast to ($75.1M), adding that he no longer feels confident in the company's potential to receive incremental equity warrant funding from Constellation (STZ) in the near-term. For Hexo, he now sees FY21 revenue of $121.7M and $0.2M in EBITDA. He expects market pricing to become "considerably more challenged" as industry production funnels into "a limited store set" in Canada, Hundley tells investors. He keeps a Buy rating on Aphria (APHA), making it his only Buy-rated conventional Canadian cannabis company, though he cut his price target on the stock to $8 from $13. Hundley has Neutral ratings on Aurora Cannabis (ACB) and Tilray (TLRY).
10/22/19
PIPR
10/22/19
NO CHANGE
Target $12
PIPR
Overweight
Piper cuts targets in Cannabis, says Canopy and Cronos best positioned
Piper Jaffray analyst Michael Lavery revisited the four Canadian licensed producers under his coverage, namely Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON) and Tilray (TLRY). The analyst continues to believe Canopy and Cronos look best positioned. Both companies have strong cash positions to facilitate growth and have good visibility on key strategic priorities, Lavery tells investors in a research note. The analyst cut his estimates for Tilray, but he keeps an Overweight rating on the shares as he still sees growth potential in both Europe and the U.S. Lavery believes Aurora lacks visibility on key strategic growth priorities and he keeps a Neutral rating on the shares. The analyst lowered his price target for Aurora to $4 from $7, for Canopy to $36 from $40, for Cronos to $12 from $18, and for Tilray to $31 from $72.
10/25/19
JEFF
10/25/19
NO CHANGE
Target $25
JEFF
Hold
Tilray clinical trial update yesterday a positive, says Jefferies
Tilray yesterday announced that it has successfully imported cannabis into the U.S. from Canada in support of a new clinical trial related to a breast cancer condition, Jefferies analyst Owen Bennett tells investors in a research note. With much of Tilray's future value dependent on delivery in the medical space, this update is a positive, contends the analyst. In addition, with the clinical trial happening in the U.S., "relationships such as this can only support Tilray in supporting US market penetration should it become federally permissible," says Bennett. He believes the news will boost sentiment for Tilray's medical outlook. The analyst keeps a Hold rating on the shares with a $25 price target.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$63.96

1.565 (2.51%)

07:43
12/13/19
12/13
07:43
12/13/19
07:43
Upgrade
Bristol-Myers rating change  »

Bristol-Myers upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FII

Federated Investors

$34.41

0.41 (1.21%)

07:42
12/13/19
12/13
07:42
12/13/19
07:42
Downgrade
Federated Investors rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKX

Skechers

$41.65

0.89 (2.18%)

07:38
12/13/19
12/13
07:38
12/13/19
07:38
Upgrade
Skechers rating change  »

Skechers upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$56.47

0.16 (0.28%)

07:38
12/13/19
12/13
07:38
12/13/19
07:38
Recommendations
Oracle analyst commentary  »

Oracle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OPI

Office Properties

$32.93

-1.02 (-3.00%)

07:37
12/13/19
12/13
07:37
12/13/19
07:37
Downgrade
Office Properties rating change  »

Morgan Stanley cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THTX

Theratechnologies

$3.05

-0.01 (-0.33%)

07:36
12/13/19
12/13
07:36
12/13/19
07:36
Hot Stocks
Theratechnologies reports results from in vitro, in vivo experiments on TH-1902 »

Theratechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HWC

Hancock Whitney

$42.61

1.07 (2.58%)

07:35
12/13/19
12/13
07:35
12/13/19
07:35
Upgrade
Hancock Whitney rating change  »

Hancock Whitney upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$11.44

0.46 (4.19%)

, ATVI

Activision Blizzard

$58.60

2.12 (3.75%)

07:35
12/13/19
12/13
07:35
12/13/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

GE

General Electric

$11.44

0.46 (4.19%)

ATVI

Activision Blizzard

$58.60

2.12 (3.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 29

    Jan

NPO

EnPro

$66.48

2.53 (3.96%)

07:34
12/13/19
12/13
07:34
12/13/19
07:34
Conference/Events
EnPro to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$293.92

1.71 (0.59%)

07:33
12/13/19
12/13
07:33
12/13/19
07:33
Hot Stocks
Breaking Hot Stocks news story on Biogen »

Biogen to discontinue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$293.92

1.71 (0.59%)

07:32
12/13/19
12/13
07:32
12/13/19
07:32
Hot Stocks
Biogen: Primary endpoint not statistically significant in Phase 2 PASSPORT study »

Biogen announced topline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

07:32
12/13/19
12/13
07:32
12/13/19
07:32
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CG

Carlyle Group

$29.83

-0.36 (-1.19%)

07:31
12/13/19
12/13
07:31
12/13/19
07:31
Hot Stocks
Funds advised by Apax Partners to acquire Coalfire from Carlyle Group, Chertoff »

Funds advised by Apax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ADBE

Adobe

$305.76

2.01 (0.66%)

07:30
12/13/19
12/13
07:30
12/13/19
07:30
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SAFM

Sanderson Farms

$166.66

2.5 (1.52%)

07:30
12/13/19
12/13
07:30
12/13/19
07:30
Initiation
Sanderson Farms initiated  »

Sanderson Farms initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

ORCL

Oracle

$56.47

0.16 (0.28%)

07:30
12/13/19
12/13
07:30
12/13/19
07:30
Recommendations
Oracle analyst commentary  »

Oracle shares to come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$327.39

7.53 (2.35%)

07:28
12/13/19
12/13
07:28
12/13/19
07:28
Recommendations
Broadcom analyst commentary  »

Broadcom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCLH

Norwegian Cruise Line

$56.12

0.72 (1.30%)

07:27
12/13/19
12/13
07:27
12/13/19
07:27
Recommendations
Norwegian Cruise Line analyst commentary  »

Norwegian Cruise Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

07:26
12/13/19
12/13
07:26
12/13/19
07:26
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ADBE

Adobe

$305.76

2.01 (0.66%)

07:25
12/13/19
12/13
07:25
12/13/19
07:25
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

DCP

DCP Midstream

$23.70

-0.56 (-2.31%)

07:25
12/13/19
12/13
07:25
12/13/19
07:25
Initiation
DCP Midstream initiated  »

DCP Midstream initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

07:25
12/13/19
12/13
07:25
12/13/19
07:25
Conference/Events
UBS analyst manley to hold an analyst/industry conference call »

Analyst Manley discusses…

TDOC

Teladoc

$77.06

-0.36 (-0.46%)

07:24
12/13/19
12/13
07:24
12/13/19
07:24
Initiation
Teladoc initiated  »

Teladoc initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIMT

Aimmune

$31.60

0.78 (2.53%)

07:22
12/13/19
12/13
07:22
12/13/19
07:22
Downgrade
Credit Suisse downgrades Aimmune with peanut allergy approval widely expected »

Credit Suisse analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$162.94

-4.5 (-2.69%)

07:22
12/13/19
12/13
07:22
12/13/19
07:22
Downgrade
Nordson rating change  »

Nordson downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.